论文部分内容阅读
为探讨CD10 5标记的微血管密度 (MVD )与乳腺肿瘤临床病理和预后的关系 ,作者应用免疫组织化学SP法及CD10 5单克隆抗体测定了 5 3例乳腺癌 ,3 0例乳腺良性肿块 ,2 0例正常乳腺组织中CD10 5标记的MVD ,并对其与临床病理因素和术后生存率进行分析。结果示正常乳腺组织、乳腺良性肿块 ,乳腺癌CD10 5的表达值依次为 3 .12± 1.18,10 .5 0± 3 .41和 5 0 .0 3± 15 .41,乳腺癌组织明显高于前两组 (P <0 .0 1)。用MVD表示的CD10 5值与TNM分期、淋巴结转移等病理因素无关。单、多因素分析结果表明 ,CD 10 5标记的MVD是乳腺癌的独立预后因素。提示CD10 5是乳腺癌血管生成的重要因素 ,它在乳腺癌中的表达较良性肿块及正常乳腺明显增高 ;CD10 5标记的MVD与临床病理因素无关 ,它可作为乳腺癌的一种重要预后指标。
To investigate the relationship between CD105-labeled microvessel density (MVD) and the clinicopathologic features and prognosis of breast tumors, the authors used immunohistochemical SP method and CD10 5 monoclonal antibody to detect 53 breast cancer cases, 30 breast benign tumors, 2 0 cases of normal breast tissue CD10 5 labeled MVD, and its clinical and pathological factors and postoperative survival rates were analyzed. The results showed that the expression of CD10 5 in normal breast tissue, benign breast and breast cancer was 3.12 ± 1.18, 10 .5 ± 3.41 and 5.0 ± 15.41, respectively, which was significantly higher than that in breast cancer The first two groups (P <0. 01). The CD105 value expressed by MVD was not related to the pathological factors such as TNM stage and lymph node metastasis. Single and multivariate analysis showed that CD105-labeled MVD was an independent prognostic factor for breast cancer. It is suggested that CD10 5 is an important factor of angiogenesis in breast cancer and its expression in breast cancer is significantly higher than that in benign tumors and normal breast. CD10 5 -labeled MVD is not associated with clinicopathological factors and may be an important prognostic indicator of breast cancer .